For the Inventor, By the Inventor

Enter assignee name

Hyderabad Telangana, India

Suven Life Sciences Limited

USPTO Granted Patents = 55

% Expired Patents = 34.5

CIPO Patents = 26

EPO Patents = 48

Forward Citations = 55

Loading Chart...

Loading Chart...

85 inventors (with patents filed for the assignee):

Venkateswarlu Jasti (53 out of 59 patents)

Ramakrishna Nirogi (37 out of 40 patents)

Anil Karbhari Shinde (35 out of 37 patents)

4. Abdul Rasheed Mohammed (19 out of 20 patents)

5. Pradeep Jayarajan (19 out of 20 patents)

6. Rama Sastri Kambhampati (16 out of 17 patents)

7. Gopinadh Bhyrapuneni (12 out of 13 patents)

8. Venkata Satya Nirogi Ramakrishna (9 out of 10 patents)

9. Ramasastri Kambhampati (8 out of 9 patents)

10. Vijay Sidram Benade (7 out of 7 patents)

11. Ishtiyaque Ahmad (7 out of 12 patents)

12. Rajesh Kumar Badange (6 out of 6 patents)

13. Nagaraj Vishwottam Kandikere (6 out of 6 patents)

14. Venkata Satya Veerabhadra Vadlamudi Rao (6 out of 7 patents)

15. Ramkumar Subramanian (5 out of 5 patents)

Core Competencies:

Pharmaceutical Compositions

CNS Disorders

5-HT4 Receptor Agonists

Muscarinic M1 Receptor Modulators

Histamine H3 Receptor Ligands

5-HT6 Receptor Antagonists

Piperidine Compounds

Acrylamide Compounds

Serotonin Receptor Affinity

Indole Derivatives

Polycyclic Amides

Tetracyclic Indoles

55 patents: Sort by Forward Citations

1. 12721846 - Methods for treating behavioral and psychological symptoms in patients with dementia (2026-09-01),

2. 12629365 - Pharmaceutical compositions of 5-HTreceptor antagonist (2026-05-19),

3. 12397003 - Amorphous pharmaceutical compositions of abiraterone acetate (2025-08-26),

4. 12391698 - Substituted piperidines and piperazines and methods for the treatment of CNS disorders (2025-08-19),

5. 12338236 - Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders (2025-06-24),

6. 12285421 - Uses of a 5-HT4 receptor agonist (2025-04-29),

7. 12275746 - Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-HT4 receptor agonists (2025-04-14),

8. 12156871 - Substituted azacycles as muscarinic M1 receptor positive allosteric modulators (2024-12-03),

9. 12122779 - Pyrrolo-pyridazine derivatives as muscarinic M1 receptor positive allosteric modulators (2024-10-22),

10. 11622967 - Method of treatment with histamine-3 receptor inverse agonist (2023-04-11),

11. 11458135 - Combination of pure 5-HT6 receptor antagonists with acetylcholinesterase inhibitors (2022-10-04),

12. 11278530 - Polycyclic amides as muscarinic M1 receptor positive allosteric modulators (2022-03-22),

13. 11253514 - Triple combination of pure 5-HTreceptor antagonists, acetylcholinesterase inhibitors and NMDA receptor antagonist (2022-02-22),

14. 11234979 - Heteroaryl compounds as muscarinic M1 receptor positive allosteric modulators (2022-02-01),

15. 11116764 - Combination of pure 5-HT6 receptor antagonists with NMDA receptor antagonist (2021-09-14),

Suven Life Sciences Limited is a research-focused pharmaceutical company specializing in discovering, developing, and commercializing innovative therapeutics. With a diverse portfolio, Suven focuses on drug discovery and development for central nervous system disorders. They have a strong presence in the global market and are committed to improving the lives of patients through their novel pharmaceutical products.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

55 Patents

#3 in Hyderabad Telangana

#34 in India

#12,878 in the World

Hyderabad Telangana, India

Suven Life Sciences Limited

Forward Citations = 55

85 inventors:

Venkateswarlu Jasti (53 out of 59 patents)

Ramakrishna Nirogi (37 out of 40 patents)

Anil Karbhari Shinde (35 out of 37 patents)

4. Abdul Rasheed Mohammed (19 out of 20 patents)

5. Pradeep Jayarajan (19 out of 20 patents)

Please report any incorrect information to [email protected]

Loading…